The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease.
In agreement with previous authors we found patients with Graves' disease to have an increased incidence of the DR 3 antigen. We could find no association, however, between the presence of the antigen and relapse after carbimazole treatment. A concordant HLA status and thyrotrophin receptor antibody (TRAb) index, obtained at either 6 or 12 months after the start of treatment could only predict cases of relapse and remission in a minority of patients making this of very limited clinical use. The TRAb index obtained at 12 months after the start of medical therapy could accurately predict cases of relapse and remission for the next 3 years in 24/30 patients studied.
D000328:Adult; D000906:Antibodies; D002231:Carbimazole / Q000627:therapeutic use; D005260:Female; D006111:Graves Disease / Q000188:drug therapy; D006681:HLA-D Antigens / Q000032:analysis*; D006684:HLA-DR Antigens / Q000032:analysis*; D015803:HLA-DR3 Antigen; D006801:Humans; D008297:Male; D011379:Prognosis; D011989:Receptors, Thyrotropin / Q000276:immunology*; D013971:Thyrotoxicosis / Q000276:immunology*
D000906:Antibodies; D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D015803:HLA-DR3 Antigen; D011989:Receptors, Thyrotropin; D002231:Carbimazole